User Tag List

+ Reply to Thread
Page 2 of 2 FirstFirst 12
Results 11 to 13 of 13

Thread: Cancer breakthroughs, research & treatment

  1. #11

    tPF Moderator
    Original Ranter
    V.I.P
    Points: 700,380, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 99.9%
    Achievements:
    SocialCreated Album picturesOverdrive50000 Experience PointsVeteran
    Awards:
    Discussion Ender
    Peter1469's Avatar tPF Moderator
    Karma
    262384
    Join Date
    Jun 2011
    Location
    Northern VA
    Posts
    106,021
    Points
    700,380
    Level
    100
    Thanks Given
    57,912
    Thanked 41,284x in 29,248 Posts
    Mentioned
    1824 Post(s)
    Tagged
    0 Thread(s)
    Rep Power
    2735
    Quote Originally Posted by Dangermouse View Post
    While there are advances being made in many areas, the "cure" for cancer has been ten years away for decades.
    That is not correct.
    Alea iacta est

    Check out the blog.


  2. #12
    Points: 71,508, Level: 65
    Level completed: 26%, Points required for next Level: 1,642
    Overall activity: 62.0%
    Achievements:
    1 year registered50000 Experience PointsSocial
    JDubya's Avatar Senior Member
    Karma
    46776
    Join Date
    Feb 2015
    Posts
    8,427
    Points
    71,508
    Level
    65
    Thanks Given
    1,164
    Thanked 2,259x in 1,788 Posts
    Mentioned
    83 Post(s)
    Tagged
    0 Thread(s)
    Rep Power
    477
    Quote Originally Posted by Dangermouse View Post
    While there are advances being made in many areas, the "cure" for cancer has been ten years away for decades.
    In past decades the kind of technology didn't exist that is available today.

    Same with the level of knowledge about genetic engineering.

  3. The Following User Says Thank You to JDubya For This Useful Post:

    Peter1469 (04-17-2016)

  4. #13
    Points: 10,499, Level: 24
    Level completed: 57%, Points required for next Level: 351
    Overall activity: 29.0%
    Achievements:
    VeteranTagger Second Class10000 Experience Points
    waltky's Avatar Senior Member
    Karma
    638
    Join Date
    Oct 2012
    Posts
    2,360
    Points
    10,499
    Level
    24
    Thanks Given
    348
    Thanked 329x in 287 Posts
    Mentioned
    9 Post(s)
    Tagged
    0 Thread(s)
    Rep Power
    12

    Immuno-therapy drugs to fight cancer could be approved next year...

    Cancer cell therapies could be approved next year: Juno, Kite Pharma
    Sat Jun 4, 2016 - A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells could begin reaching patients next year, according to companies presenting new data at the annual meeting of the American Society of Clinical Oncology.
    In interviews with Reuters, Kite Pharma Inc (KITE.O) and Juno Therapeutics Inc (JUNO.O) both said they could receive initial regulatory approvals next year for a type of immunotherapy treatment known as chimeric antigen receptor T-cell (CAR-T) therapies. CAR-T therapies involve a complicated process of extracting immune system T cells from an individual patient, altering their DNA to sharpen their ability to spot and kill cancer cells, and infusing them back into the same patient. The technique is being tested against a range of different cancer types, but first in blood cancers. Kite aims to file this year for U.S. Food and Drug Administration approval of its therapy, KTE-C19, for patients with diffuse large B-cell lymphoma (DLBCL), according to Chief Medical Officer David Chang.

    Juno Chief Executive Officer Hans Bishop said adult patients with acute lymphoblastic leukemia (ALL) are now being enrolled in a mid-stage trial of the company's most advanced product, JCAR015, that "we believe will support accelerated approval." He said JCAR015 "could be approved as soon as 2017." Data presented on Saturday showed that 77 percent of patients with advanced ALL achieved a "complete response," meaning cancer remission, when treated with chemotherapy followed by Juno's cell therapy. For the trial patients with minimal disease, 90 percent achieved remission, researchers said. Twenty-seven percent of patients in the JCAR15 trial experienced a severe inflammatory response to the altered cells, and 15 percent had serious nervous system side effects.


    Preparations of media for cultivating cancer cells, being made in cancer research laboratories at the Old Road Campus research building at Oxford University, in Oxford, Britain

    Bishop said Juno has developed an assay to determine which patients are likely to experience risky side effects, but said the company has not yet disclosed the details. A separate National Institutes of Health early-stage study involving Kite's CAR-T drug and low-dose chemotherapy included 19 patients with various subtypes of DLBCL. Of those, eight patients achieved remission, five had partial responses, two had stable disease, and four had their cancer get worse. Two trial patients with advanced follicular lymphoma also obtained remissions. "In the near future, CAR-T cells will likely be a standard therapy for lymphoma," said lead study author James Kochenderfer, an investigator at the National Cancer Institute.

    Some patients treated with the still-experimental therapies have remained cancer free, but the jury is out on whether that will continue, or whether they will need new treatment. "Some of these responses are amazing in patients who would never have responded to anything," said ASCO President Dr Julie Vose. "The question is, is it practical? We are now seeing results for more patients, and longer follow up." Juno's Bishop said he is certain that the benefit of CAR-T therapies will be shown to outweigh any risks. "These are patients that are relapsed and refractory. They are going to die of their disease," he said. "We can get 90 to 100 percent of them into remission, and a meaningful percentage of them have durable remission."

    http://www.reuters.com/article/us-he...-idUSKCN0YQ0T1

+ Reply to Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts


Critical Acclaim
Single Sign On provided by vBSSO